Vaccination against the highly abused prescription opioid oxycodone has shown pre-clinical efficacy for blocking oxycodone effects. The current study further evaluated a candidate vaccine composed of oxycodone derivatized at the C6 position (6OXY) conjugated to the native keyhole limpet hemocyanin (nKLH) carrier protein. To provide an oxycodone vaccine formulation suitable for human studies, we studied the effect of alternative carriers and adjuvants on the generation of oxycodone-specific serum antibody and B cell responses, and the effect of immunization on oxycodone distribution and oxycodone-induced antinociception in mice and rats. 6OXY conjugated to tetanus toxoid (TT) or a GMP grade KLH dimer (dKLH) was as effective as 6OXY conjugated to the nKLH decamer in mice and rats, while the 6OXY hapten conjugated to a TT-derived peptide was not effective in preventing oxycodone-induced antinociception in mice. Immunization with 6OXY-TT s.c. absorbed on alum adjuvant provided similar protection to 6OXY-TT administered i.p. with Freund’s adjuvant in rats. The toll-like receptor 4 (TLR4) agonist monophosphoryl lipid A (MPLA) adjuvant, alone or in combination with alum, offered no advantage over alum alone for generating oxycodone-specific serum antibodies or 6OXY-specific antibody secreting B cells in mice vaccinated with 6OXY-nKLH or 6OXY-TT. The immunogenicity of oxycodone vaccines may be modulated by TLR4 signaling since responses to 6OXY-nKLH in alum were decreased in TLR4-deficient mice. These data suggest that TT, nKLH and dKLH carriers provide consistent 6OXY conjugate vaccine immunogenicity across species, strains and via different routes of administration, while adjuvant formulations may need to be tailored to individual immunogens or patient populations.
References
[1]
UNODC (2012) World Drug Report 2012.
[2]
National Survey on Drug Use and Health: National Findings (2013)
[3]
Binswanger IA, Blatchford PJ, Mueller SR, Stern MF (2013) Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med 159: 592–600.
[4]
Shen XY, Orson FM, Kosten TR (2012) Vaccines against drug abuse. Clin Pharmacol Ther 91: 60–70.
[5]
Pryde DC, Jones LH, Gervais DP, Stead DR, Blakemore DC, et al. (2013) Selection of a novel anti-nicotine vaccine: influence of antigen design on antibody function in mice. PLoS One 8: e76557. doi: 10.1371/journal.pone.0076557
[6]
Cai X, Whitfield T, Moreno AY, Grant Y, Hixon MS, et al.. (2013) Probing the Effects of Hapten Stability on Cocaine Vaccine Immunogenicity. Mol Pharm.
[7]
de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR (2013) Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine doi: 10.1016/j.vaccine.2013.10.051
[8]
Hu Y, Zheng H, Huang W, Zhang C (2013) A novel and efficient nicotine vaccine using nano-lipoplex as a delivery vehicle. Hum Vaccin Immunother 10. doi: 10.4161/hv.26635
[9]
McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, et al. (2013) Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 16: 50–56. doi: 10.1016/j.intimp.2013.03.021
[10]
Lockner JW, Ho SO, McCague KC, Chiang SM, Do TQ, et al. (2013) Enhancing nicotine vaccine immunogenicity with liposomes. Bioorg Med Chem Lett 23: 975–978. doi: 10.1016/j.bmcl.2012.12.048
[11]
Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX (2012) High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine 31: 159–164. doi: 10.1016/j.vaccine.2012.10.069
[12]
Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, et al. (2013) Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 31: 2804–2810. doi: 10.1016/j.vaccine.2013.04.027
[13]
Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, et al. (2012) Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 83: 543–550. doi: 10.1016/j.bcp.2011.11.004
[14]
Pravetoni M, Le Naour M, Tucker AM, Harmon TM, Hawley TM, et al. (2013) Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. J Med Chem 56: 915–923. doi: 10.1021/jm3013745
[15]
Pravetoni M, Le Naour M, Harmon T, Tucker A, Portoghese PS, et al. (2012) An oxycodone conjugate vaccine elicits oxycodone-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. J Pharmacol Exp Ther doi: 10.1124/jpet.111.189506
[16]
Musselli C, Livingston PO, Ragupathi G (2001) Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol 127 Suppl 2: R20–26. doi: 10.1007/bf01470995
[17]
Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK (2011) Different B cell populations mediate early and late memory during an endogenous immune response. Science 331: 1203–1207. doi: 10.1126/science.1201730
[18]
Taylor JJ, Martinez RJ, Titcombe PJ, Barsness LO, Thomas SR, et al. (2012) Deletion and anergy of polyclonal B cells specific for ubiquitous membrane-bound self-antigen. J Exp Med 209: 2065–2077. doi: 10.1084/jem.20112272
[19]
Taylor JJ, Pape KA, Jenkins MK (2012) A germinal center-independent pathway generates unswitched memory B cells early in the primary response. J Exp Med 209: 597–606. doi: 10.1084/jem.20111696
[20]
Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M (2014) Hapten-specific naive B cells are biomarkers of vaccine efficacy against drugs of abuse. J Immunol Methods doi: 10.1016/j.jim.2014.01.010
[21]
Schellenberger MT, Grova N, Farinelle S, Willieme S, Revets D, et al. (2012) Immunogenicity of a promiscuous T cell epitope peptide based conjugate vaccine against benzo[a]pyrene: redirecting antibodies to the hapten. PLoS One 7: e38329. doi: 10.1371/journal.pone.0038329
[22]
O'Neill LA, Bryant CE, Doyle SL (2009) Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 61: 177–197. doi: 10.1124/pr.109.001073
[23]
Lebrec H, Hock MB, Sundsmo JS, Mytych DT, Chow H, et al. (2013) T-cell-dependent antibody responses in the rat: Forms and sources of keyhole limpet hemocyanin matter. J Immunotoxicol doi: 10.3109/1547691x.2013.822948
[24]
Anton B, Leff P (2006) A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24: 3232–3240. doi: 10.1016/j.vaccine.2006.01.047
[25]
Matyas GR, Mayorov AV, Rice KC, Jacobson AE, Cheng K, et al. (2013) Liposomes containing monophosphoryl lipid A: A potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine doi: 10.1016/j.vaccine.2013.04.027
[26]
Astronomo RD, Burton DR (2010) Carbohydrate vaccines: developing sweet solutions to sticky situations? Nat Rev Drug Discov 9: 308–324. doi: 10.1038/nrd3012
[27]
Livingston PO, Ragupathi G (2006) Cancer vaccines targeting carbohydrate antigens. Hum Vaccin 2: 137–143. doi: 10.1007/978-1-59259-680-5_11
[28]
Miles D, Roche H, Martin M, Perren TJ, Cameron DA, et al. (2011) Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16: 1092–1100. doi: 10.1634/theoncologist.2010-0307
[29]
Gilewski TA, Ragupathi G, Dickler M, Powell S, Bhuta S, et al. (2007) Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 13: 2977–2985. doi: 10.1158/1078-0432.ccr-06-2189
[30]
Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, et al. (2009) Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116–1123. doi: 10.1001/archgenpsychiatry.2009.128
[31]
Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, et al. (2002) Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20: 1196–1204. doi: 10.1016/s0264-410x(01)00425-x
[32]
Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED, et al. (2011) Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 89: 392–399.
[33]
Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, et al. (2005) Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther 78: 456–467.
[34]
Cornuz J, Zwahlen S, Jungi WF, Osterwalder J, Klingler K, et al. (2008) A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 3: e2547. doi: 10.1371/journal.pone.0002547
[35]
Maurer P, Jennings GT, Willers J, Rohner F, Lindman Y, et al. (2005) A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 35: 2031–2040. doi: 10.1002/eji.200526285
[36]
Sanderson SD, Cheruku SR, Padmanilayam MP, Vennerstrom JL, Thiele GM, et al. (2003) Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol 3: 137–146. doi: 10.1016/s1567-5769(02)00260-6
[37]
Bremer PT, Janda KD (2012) Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem 55: 10776–10780. doi: 10.1021/jm301262z
[38]
Wang X, Loram LC, Ramos K, de Jesus AJ, Thomas J, et al. (2012) Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci U S A 109: 6325–6330. doi: 10.1073/pnas.1200130109
[39]
Picciotto MR, Wickman K (1998) Using knockout and transgenic mice to study neurophysiology and behavior. Physiol Rev 78: 1131–1163.
[40]
Grondahl-Yli-Hannuksela K, Vuononvirta J, Barkoff AM, Viander M, Van Der Meeren O, et al. (2012) Gene polymorphism in toll-like receptor 4: effect on antibody production and persistence after acellular pertussis vaccination during adolescence. J Infect Dis 205: 1214–1219. doi: 10.1093/infdis/jis182
[41]
Kimman TG, Banus S, Reijmerink N, Reimerink J, Stelma FF, et al. (2008) Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination. PLoS One 3: e3665. doi: 10.1371/journal.pone.0003665
[42]
Schroder NW, Schumann RR (2005) Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. Lancet Infect Dis 5: 156–164. doi: 10.1016/s1473-3099(05)70023-2
[43]
Tsukamoto H, Fukudome K, Takao S, Tsuneyoshi N, Ohta S, et al. (2013) Reduced surface expression of TLR4 by a V254I point mutation accounts for the low lipopolysaccharide responder phenotype of BALB/c B cells. J Immunol 190: 195–204. doi: 10.4049/jimmunol.1201047
[44]
Yamakawa N, Ohto U, Akashi-Takamura S, Takahashi K, Saitoh S, et al. (2013) Human TLR4 polymorphism D299G/T399I alters TLR4/MD-2 conformation and response to a weak ligand monophosphoryl lipid A. Int Immunol 25: 45–52. doi: 10.1093/intimm/dxs084
